Company profile for Matinas BioPharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the om...
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1545 Route 206, Suite 302 Bedminster, New Jersey 07921
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/03/11/3040409/32419/en/Matinas-BioPharma-Appoints-Seasoned-Biotech-Leaders-to-Board-of-Directors.html

GLOBENEWSWIRE
11 Mar 2025

https://www.globenewswire.com/news-release/2025/02/13/3026339/32419/en/Matinas-BioPharma-Announces-Agreement-for-the-Acquisition-of-Preferred-Stock-and-Appointment-of-Dr-Robin-L-Smith-to-the-Board-of-Directors.html

GLOBENEWSWIRE
13 Feb 2025

https://www.globenewswire.com/news-release/2025/02/07/3022725/32419/en/Matinas-BioPharma-Appoints-Evelyn-D-An-to-Board-of-Directors-as-Audit-Committee-Chair.html

GLOBENEWSWIRE
07 Feb 2025

https://www.globenewswire.com/news-release/2025/01/10/3007959/32419/en/Matinas-BioPharma-Receives-NYSE-Noncompliance-Notice.html

GLOBENEWSWIRE
10 Jan 2025

https://www.globenewswire.com/news-release/2024/10/31/2972421/32419/en/Matinas-BioPharma-Announces-the-Termination-of-MAT2203-Partnership-Negotiations-and-Implements-Immediate-Workforce-Reduction.html

GLOBENEWSWIRE
31 Oct 2024

https://www.globenewswire.com/news-release/2024/08/14/2930455/32419/en/Matinas-BioPharma-Reports-Second-Quarter-2024-Financial-Results-and-Provides-a-Business-Update.html

GLOBENEWSWIRE
14 Aug 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty